Concepedia

Author

G. Bodoky

Unified Szent István and Szent László HospitalORCID

Also Known As

Elke Jaeger, G BODOKY, G Bodoky, G. Bodoky, G.Y. Bodoky, Gy. Bodoky, Gyorgy Bodoky, György Bodoky, János Bezsilla

286

Publications

33K

Citations

54

H-Index

95

Concepts

All Affiliations

Unified Szent István and Szent László HospitalNational Cancer Center Hospital EastEli Lilly (United States)KU LeuvenAichi Cancer Center
GB

About

G. Bodoky is an author at Unified Szent István and Szent László Hospital specializing in medicine, oncology, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

38

67

19.8K

2

Health Sciences

19

29

4.9K

3

Public Health

3

3

45

4

Engineering

2

2

88

5

Biomedical Engineering

1

1

58

G. Bodoky

×

110

Publications

32.6K

Citations

54

H-Index

YearCitations

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

Eric Van Cutsem, Claus-Henning Köhne, Erika Hitre,

New England Journal of Medicine

2009

3.8K

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

Jordi Bruix, Shukui Qin, Philippe Merle,

The Lancet

2016

3.6K

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

Eric Van Cutsem, Andrés Cervantes, René Adam,

Annals of Oncology

2016

3.3K

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

H. Wilke, Kei Muro, Eric Van Cutsem,

The Lancet Oncology

2014

2.4K

Panitumumab–FOLFOX4 Treatment and <i>RAS</i> Mutations in Colorectal Cancer

Jean‐Yves Douillard, Kelly S. Oliner, Salvatore Siena,

New England Journal of Medicine

2013

2.2K

Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study

Jean‐Yves Douillard, Salvatore Siena, James T. Cassidy,

Journal of Clinical Oncology

2010

1.8K

ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making

Hans‐Joachim Schmoll, Eric Van Cutsem, Alexander Stein,

Annals of Oncology

2012

1.5K

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

Andrea Wang‐Gillam, Chung‐Pin Li, G. Bodoky,

The Lancet

2015

1.2K

Prognostic Role of <i>KRAS</i> and <i>BRAF</i> in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial

Arnaud Roth, Sabine Tejpar, Mauro Delorenzi,

Journal of Clinical Oncology

2009

1.1K

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

Josep Tabernero, Takayuki Yoshino, Allen Lee Cohn,

The Lancet Oncology

2015

938

Page 1